An Autocrine Wnt5a Loop Promotes NF-κB Pathway Activation and Cytokine/Chemokine Secretion in Melanoma.
Autocrine Communication
Cell Line, Tumor
Chemokines
/ metabolism
Cytokines
/ metabolism
Dishevelled Proteins
/ metabolism
Humans
I-kappa B Kinase
/ metabolism
I-kappa B Proteins
/ metabolism
Melanoma
/ metabolism
NF-kappa B
/ antagonists & inhibitors
Phosphorylation
Proto-Oncogene Proteins c-akt
/ metabolism
Receptor Tyrosine Kinase-like Orphan Receptors
/ metabolism
Signal Transduction
TNF Receptor-Associated Factor 2
/ metabolism
Transcription Factor RelA
/ metabolism
Wnt-5a Protein
/ metabolism
Akt
NF-κB
Wnt5a
chemokine
cytokine
melanoma
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
10 09 2019
10 09 2019
Historique:
received:
18
07
2019
revised:
29
08
2019
accepted:
05
09
2019
entrez:
13
9
2019
pubmed:
13
9
2019
medline:
12
6
2020
Statut:
epublish
Résumé
Wnt5a signaling has been implicated in the progression of cancer by regulating multiple cellular processes, largely migration and invasion, epithelial-mesenchymal transition (EMT), and metastasis. Since Wnt5a signaling has also been involved in inflammatory processes in infectious and inflammatory diseases, we addressed the role of Wnt5a in regulating NF-κB, a pivotal mediator of inflammatory responses, in the context of cancer. The treatment of melanoma cells with Wnt5a induced phosphorylation of the NF-κB subunit p65 as well as IKK phosphorylation and IκB degradation. By using cDNA overexpression, RNA interference, and dominant negative mutants we determined that ROR1, Dvl2, and Akt (from the Wnt5a pathway) and TRAF2 and RIP (from the NF-κB pathway) are required for the Wnt5a/NF-κB crosstalk. Wnt5a also induced p65 nuclear translocation and increased NF-κB activity as evidenced by reporter assays and a NF-κB-specific upregulation of RelB, Bcl-2, and Cyclin D1. Further, stimulation of melanoma cells with Wnt5a increased the secretion of cytokines and chemokines, including IL-6, IL-8, IL-11, and IL-6 soluble receptor, MCP-1, and TNF soluble receptor I. The inhibition of endogenous Wnt5a demonstrated that an autocrine Wnt5a loop is a major regulator of the NF-κB pathway in melanoma. Taken together, these results indicate that Wnt5a activates the NF-κB pathway and has an immunomodulatory effect on melanoma through the secretion of cytokines and chemokines.
Identifiants
pubmed: 31510045
pii: cells8091060
doi: 10.3390/cells8091060
pmc: PMC6770184
pii:
doi:
Substances chimiques
Chemokines
0
Cytokines
0
DVL2 protein, human
0
Dishevelled Proteins
0
I-kappa B Proteins
0
NF-kappa B
0
TNF Receptor-Associated Factor 2
0
Transcription Factor RelA
0
WNT5A protein, human
0
Wnt-5a Protein
0
ROR1 protein, human
EC 2.7.10.1
Receptor Tyrosine Kinase-like Orphan Receptors
EC 2.7.10.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
I-kappa B Kinase
EC 2.7.11.10
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Références
Pathobiology. 2013;80(5):235-44
pubmed: 23615002
J Biol Chem. 2014 Jul 25;289(30):21028-39
pubmed: 24891513
Eur J Cancer. 2017 Sep;83:247-257
pubmed: 28756137
Cell Biol Int. 2016 Feb;40(2):177-87
pubmed: 26462870
J Biol Chem. 2002 Feb 22;277(8):5977-81
pubmed: 11742004
Mol Carcinog. 2015 Jun;54 Suppl 1:E112-21
pubmed: 25156800
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancers (Basel). 2016 Aug 26;8(9):null
pubmed: 27571105
Mol Carcinog. 2016 Nov;55(11):1772-1785
pubmed: 26509654
Oncotarget. 2016 Oct 11;7(41):67674-67684
pubmed: 27608847
Med Sci Monit. 2016 Dec 22;22:5058-5067
pubmed: 28005837
Clin Cancer Res. 2008 Sep 15;14(18):5825-32
pubmed: 18794093
Oncol Rep. 2005 Dec;14(6):1583-8
pubmed: 16273260
Mol Cell Biol. 2005 May;25(9):3475-82
pubmed: 15831454
J Immunol Res. 2014;2014:149185
pubmed: 24901008
Cancer Res. 2008 Dec 15;68(24):10205-14
pubmed: 19074888
Biomed Pharmacother. 2018 Dec;108:1415-1424
pubmed: 30372844
Pigment Cell Res. 2006 Aug;19(4):290-302
pubmed: 16827748
Cancer Cell. 2003 Nov;4(5):349-60
pubmed: 14667502
Pigment Cell Res. 2006 Apr;19(2):112-24
pubmed: 16524427
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Br J Cancer. 2009 Jul 21;101(2):209-14
pubmed: 19603030
FEBS Lett. 2004 Jul 30;571(1-3):50-4
pubmed: 15280016
Anticancer Res. 2016 Jul;36(7):3229-41
pubmed: 27354579
J Bone Miner Res. 2012 Mar;27(3):575-85
pubmed: 22162112
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Cell Mol Life Sci. 2016 Feb;73(3):567-87
pubmed: 26514730
Oncogene. 2010 Apr 8;29(14):2036-46
pubmed: 20101234
J Biol Chem. 2007 Jun 8;282(23):17259-71
pubmed: 17426020
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3047-52
pubmed: 18287027
Int J Mol Med. 2009 Jun;23(6):763-9
pubmed: 19424602
Cancer Res. 2002 Dec 15;62(24):7335-42
pubmed: 12499277
BMC Cancer. 2014 Jul 03;14:480
pubmed: 24993819
Cell Cycle. 2014;13(9):1400-12
pubmed: 24626186
Cells. 2016 Mar 18;5(1):null
pubmed: 26999213
Sci Signal. 2008 Sep 02;1(35):re9
pubmed: 18765832
EMBO J. 2004 Jan 28;23(2):322-32
pubmed: 14713952
Nat Rev Cancer. 2002 Apr;2(4):301-10
pubmed: 12001991
Cancer Res. 2006 Nov 1;66(21):10439-48
pubmed: 17079465
Mol Cancer. 2014 Apr 26;13:88
pubmed: 24766647
Science. 2005 Sep 16;309(5742):1857-61
pubmed: 16166517
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Immunol. 2010 Jul 15;185(2):1274-82
pubmed: 20554957
Oncogene. 2005 Mar 24;24(13):2144-54
pubmed: 15735754
J Biol Chem. 2001 Jun 1;276(22):18934-40
pubmed: 11259436
Oncotarget. 2016 Jun 21;7(25):37790-37802
pubmed: 27191257
J Exp Clin Cancer Res. 2018 Jul 24;37(1):164
pubmed: 30041677
PLoS One. 2012;7(6):e39945
pubmed: 22768179
Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19473-8
pubmed: 19901340
Int J Oncol. 2016 Apr;48(4):1391-8
pubmed: 26847533
J Clin Oncol. 2005 Dec 1;23(34):8765-73
pubmed: 16314637
Cell Biosci. 2019 Jan 3;9:3
pubmed: 30622697
Cancer Res. 2002 Jan 15;62(2):409-16
pubmed: 11809689
Cancer Cell. 2002 Apr;1(3):279-88
pubmed: 12086864
Cytokine. 2012 Oct;60(1):242-8
pubmed: 22763043
Oncotarget. 2017 Jun 13;8(24):39033-39047
pubmed: 28380463
Cancers (Basel). 2015 Sep 17;7(3):1900-24
pubmed: 26393652
Cold Spring Harb Perspect Biol. 2010 Feb;2(2):a000166
pubmed: 20182612
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Am J Physiol Gastrointest Liver Physiol. 2008 Dec;295(6):G1150-8
pubmed: 18832445
Oncogene. 2018 Mar;37(10):1399-1408
pubmed: 29249801
Cancer Cell. 2007 May;11(5):447-60
pubmed: 17482134
Nat Chem Biol. 2009 Feb;5(2):100-7
pubmed: 19125156
Br J Cancer. 2018 Mar 6;118(5):670-678
pubmed: 29381686
Acta Physiol (Oxf). 2012 Jan;204(1):17-33
pubmed: 21518267
Carcinogenesis. 2007 Jun;28(6):1178-87
pubmed: 17227781
Front Mol Neurosci. 2012 Feb 20;5:14
pubmed: 22363263
Nat Rev Immunol. 2017 Sep;17(9):559-572
pubmed: 28555670
PLoS One. 2013;8(1):e53012
pubmed: 23349696
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Int Rev Cell Mol Biol. 2015;314:117-48
pubmed: 25619716
J Cell Physiol. 2017 Jul;232(7):1611-1616
pubmed: 27859213
J Clin Invest. 2014 Jul;124(7):2877-90
pubmed: 24865425
J Exp Med. 2017 Jan;214(1):143-163
pubmed: 27979969
Proc Natl Acad Sci U S A. 2016 May 24;113(21):5993-8
pubmed: 27162350
Br J Cancer. 2014 Mar 18;110(6):1634-44
pubmed: 24518599
Cold Spring Harb Protoc. 2010 May;2010(5):pdb.prot5423
pubmed: 20439410
Nature. 2005 Apr 28;434(7037):1138-43
pubmed: 15858576
Oncogene. 2005 Feb 10;24(7):1277-83
pubmed: 15592517
Oncotarget. 2018 Apr 20;9(30):20979-20992
pubmed: 29765514
Genes Dev. 2008 Jun 1;22(11):1490-500
pubmed: 18519641
Cell. 2008 Feb 8;132(3):344-62
pubmed: 18267068
J Invest Dermatol. 2010 Apr;130(4):1073-86
pubmed: 19940859
Mol Cancer. 2013 Aug 02;12:86
pubmed: 23915189
Cancers (Basel). 2019 Apr 19;11(4):null
pubmed: 31010242
J Cell Physiol. 2014 Dec;229(12):1908-17
pubmed: 24464650